Find Academic Supervisors

• Cancer Metabolism
• Stem Cell Metabolism
• Metabolic Regulation of Cell Growth
• +5 more

Heather R. Christofk is a Professor in the Department of Biological Chemistry at the David Geffen School of Medicine at UCLA. Her research focuses on the intricate relationship between cellular metabolism and various biological processes, particularly in the contexts of cancer development, stem cell function, and viral infections. Education: PhD in Cell and Developmental Biology from Harvard University (2007) BS in Molecular, Cell, and Developmental Biology from UCLA (2001) Dr. Christofk's research program centers on understanding how metabolic pathways regulate cellular processes in both normal physiology and disease states. Her laboratory has made significant contributions to understanding how cancer cells reprogram their metabolism to support rapid growth and proliferation, with particular focus on glucose metabolism, amino acid utilization, and metabolic adaptations in tumor microenvironments. She has also pioneered work on the metabolic regulation of stem cell function, especially in hair follicle stem cells, demonstrating how metabolic pathways control stem cell activation and differentiation. Her research has important implications for developing novel therapeutic approaches that target cancer metabolism while preserving normal tissue function. Analysis of Dr. Christofk's recent publications reveals a strong focus on metabolic heterogeneity across different biological contexts. Her work spans cancer metabolism (particularly in liposarcoma, melanoma, and hepatocellular carcinoma), stem cell metabolism (especially hair follicle stem cells), viral metabolism (including Epstein-Barr virus and Zika virus), and developmental metabolism (fetal development and organogenesis). A recurring theme is how metabolic pathways serve as regulatory nodes that control cell fate decisions, tumor progression, and therapeutic responses. Selected Research Funding: Metabolic Control of Hair Follicle Stem Cell Homeostasis and Tumorigenesis (NIH R01AR070245, 2018-2023) - Co-Principal Investigator Nutrient regulation of cancer cell growth (NIH R01CA215185, 2017-2022) - Principal Investigator Regulation of the Warburg Effect in Cancer (NIH DP2OD008454, 2011-2016) - Principal Investigator Dr. Christofk's laboratory maintains active collaborations across multiple disciplines, working with clinicians, basic scientists, and computational biologists to address complex questions in metabolism and disease. Her team employs a range of cutting-edge techniques including metabolomics, stable isotope tracing, molecular biology, and in vivo models to investigate metabolic regulation in health and disease.

• Biophysics
• Epstein-Barr Virus Infections
• Infectious Disease Medicine
• +3 more

George Miller Jr. is a Professor at Yale School of Medicine , holding primary and secondary appointments in Pediatric Infectious Diseases , Epidemiology of Microbial Diseases , and Molecular Biophysics and Biochemistry . His research focuses on the mechanisms of latency and lytic replication in Epstein-Barr Virus (EBV) and Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) , particularly the role of viral and cellular transcription factors in gene regulation and DNA replication. Dr. Miller investigates how methylated DNA-binding proteins control viral gene expression, cellular gene inhibition during lytic infection, and the development of anti-viral agents that block EBV reactivation. His work spans virology, molecular biology, and infectious disease medicine, with applications in pediatric care and oncology. His recent publications highlight studies on EBV lytic cycle inhibitors, KSHV ORF50/Rta protein function, and HIV-1 isolate diversity in macrophages. Collaborations include researchers at Yale Cancer Center and Yale School of Public Health.

Kristen ConnView profile

Assistant Professor

• Virology
• Molecular Virology
• Virus-Cell Interactions
• +3 more

Kristen Conn is an Assistant Professor in the Department of Veterinary Microbiology at the University of Saskatchewan. Her research focuses on understanding how chromatin regulatory proteins mediate cellular antiviral defenses against herpesviruses. She earned a B.Sc. (Hon) in Biochemistry from the University of Saskatchewan and a Ph.D. in Biochemistry from the University of Alberta. During her postdoctoral training at the MRC-University of Glasgow Centre for Virus Research, she investigated SUMO proteins' roles in antiviral immunity. Dr. Conn's lab studies the interplay between viral transcription and host chromatin dynamics, particularly how cellular factors like histones and SUMOylation pathways restrict viral replication. Her work uses herpesviruses as models to explore how viruses counteract transcriptional silencing mechanisms. Key research areas include PML nuclear bodies, histone variant mobilization, and epigenetic regulation during viral infection. Her publications highlight contributions to understanding HSV-1's manipulation of chromatin, Epstein-Barr virus latency mechanisms, and the role of PIAS proteins in antiviral immunity. While no specific awards are listed, her work demonstrates sustained contributions to virology since 2008. Students interested in graduate studies are encouraged to contact her directly.

Rui GuoView profile

Assistant Professor

• Epstein-Barr Virus (EBV) Pathogenesis
• Viral Oncology
• Cancer Metabolism
• +5 more

Rui Guo is an Assistant Professor at Tufts University School of Medicine, affiliated with the Department of Molecular Biology and Microbiology. Their research focuses on Epstein-Barr Virus (EBV) pathogenesis, particularly its role in cancers like Burkitt lymphoma and mechanisms for developing targeted therapies. Doctor of Philosophy (2018), Kansas State University Master of Science (2013) and Bachelor of Science (2010), Yangzhou University Research interests include EBV-driven metabolic vulnerabilities in B-cells, with a focus on methyl group metabolism, mitochondrial remodeling, and lipid dynamics. Their work aims to improve cancer treatments by targeting viral dependencies. Recent publications highlight discoveries in EBV's manipulation of cardiolipin synthesis , methionine metabolism , and lysosomal iron reduction in Burkitt lymphoma. Techniques include transcriptomics , metabolomics , and CRISPR/Cas9 screening . Scientific recognition includes: National Institutes of Health Grant (2022-2026) for Epstein-Barr Virus epigenetic research

Ileana M. CristeaView profile

Associate Professor

• Virology
• Proteomics
• Molecular Biology
• +13 more

Ileana M. Cristea is the Henry L. Hillman Professor of Molecular Biology and an Associate Professor in the Department of Molecular Biology at Princeton University. She serves as the Director of Graduate Studies and leads the Cristea Lab, which focuses on the interplay between virology and proteomics. Her research aims to understand cellular defense mechanisms against viruses and viral strategies for immune evasion. Dr. Cristea's research interests lie at the interface of virology, proteomics, and molecular biology. Her lab investigates dynamic host-virus interactions, including protein-protein and protein-nucleic acid interactions during infection, DNA sensing in the nucleus, innate immune responses to herpesviruses, the role of deacetylases (HDACs and SIRTs) in viral infections, and global remodeling of cellular organelles. She develops and applies advanced proteomic tools integrated with genomics, microscopy, and bioinformatics to study these processes. Her recent publications demonstrate a strong focus on herpesviruses and human cytomegalovirus (HCMV), exploring mechanisms of viral immune evasion, host defense via DNA sensors like IFI16, organelle remodeling, and targeted proteomic assays. The research leverages cutting-edge mass spectrometry and multi-omics approaches to uncover fundamental biological insights with therapeutic implications. Her scientific achievements have been recognized with several awards: Bordoli Prize, British Mass Spectrometry Society (2001) NIDA Avant-Garde Director Pioneer Award (2008) Human Frontiers Science Program Young Investigator Award (2009) Early Career Award in Mass Spectrometry, ACS NJ Section (2011) American Society for Mass Spectrometry Research Award (2012) Molecular & Cellular Proteomics Lectureship (2013) Mallinckrodt Scholar Award (2015) Dr. Cristea is actively involved in mentoring and education. She advises PhD students, including Ji Woo Park. She is a head instructor for the summer Proteomics Course at Cold Spring Harbor Laboratory and has taught workshops at major conferences (ASMS, HUPO). She holds leadership roles in professional organizations, serving on the Executive Board of US-HUPO and chairing the Infectious Disease initiative of HUPO World. She also serves on the editorial boards of several high-impact journals, including Molecular & Cellular Proteomics , Proteomics , and Journal of Proteome Research . The Cristea Lab operates as a multidisciplinary research team, fostering collaborations with groups worldwide. Their work is supported by partnerships with organizations like the CHDI Foundation (Huntington's disease) and the Paul G. Allen Family Foundation (organelle remodeling). The lab continues to develop innovative proteomic and computational tools, such as machine-learning pipelines for predicting protein interactions.

Heike LamanView profile

Professor

• Ubiquitin ligases
• Cell cycle regulation
• Cancer biology
• +5 more

Professor Heike Laman is the Head of the Department of Pathology and Professor of Cellular and Molecular Biology at the University of Cambridge , leading research on ubiquitin ligases and their roles in disease. Her work bridges molecular mechanisms to therapeutic applications, focusing on cancer, neurodegeneration, and protein homeostasis. Current affiliation: Department of Pathology, School of the Biological Sciences Resident at Clare College since 2014 (Fellow and Graduate Admissions Tutor) Research Interests: Ubiquitin ligases orchestrate diverse cellular signals beyond protein degradation, influencing activity, localization, and interactions. Key areas include: Cancer: Investigating SCF-Fbxw7 networks in epithelial cancers and cyclin E1 accumulation Neurodegeneration: Fbxo7's role in Parkinson's disease and dopaminergic neuron survival Therapeutic Innovation: Developing PROTACs and nanobodies to target ubiquitin ligases Publication Trends: Recent work spans ubiquitin signaling in cancer metabolism, neuroprotective pathways in Parkinson's, and structure-based design of degraders. Collaborations with AstraZeneca and academic experts highlight translational focus. Scientific Awards: Recognized for academic leadership, including election to Clare College Fellowship (2014) and early career Imperial Cancer Research Fund Fellowship. Advising: Mentors PhD students in projects on ubiquitin ligases, Parkinson's, cancer metabolism, and targeted protein degradation, with lab members working in 3D organoids , mouse models , and hiPSC-derived systems . Labs & Teams: Based at the Department of Pathology (Downing Site, Cambridge), the lab collaborates across Genetics , Pharmacology , and Clinical Neurosciences , with access to the Microscopy Bioscience Platform and Cambridge Stem Cell Institute .

Andrew MacdonaldView profile

Professor

• Oncogenic viruses
• cell biology
• virology
• +1 more

Professor Andrew Macdonald is a leading expert in tumour virology at the University of Leeds, holding the position of Professor of Tumour Virology in the School of Molecular and Cellular Biology and serving as Pro-Dean for Research and Innovation in the Faculty of Biological Sciences. His work focuses on understanding how DNA tumour viruses, such as human papillomaviruses (HPV) and polyomaviruses, contribute to cancer and identifying novel therapeutic strategies. He has held roles including Head of the School of Molecular and Cellular Biology (2020–2023) and has been recognized for his research on viral mechanisms and their clinical implications. Education: BSc, University of Leeds PhD in Molecular Biology, University of Leeds (2001) Research Interests: His research integrates virology, oncology, and cell biology to study viral replication, host-pathogen interactions, and antiviral therapies. Key areas include HPV-induced cervical cancer, BK polyomavirus in kidney disease, and the role of cellular signaling pathways in viral persistence. His lab emphasizes interdisciplinary collaboration with clinicians and industry to translate findings into clinical applications. Funding & Grants: Recent funding highlights include a boost for radiotherapy research in Leeds (2024) and studies on BK nephropathy in transplantation (2023). His work has been featured in outlets like the BBC and Yorkshire Post. Labs & Teams: He leads the Macdonald Lab, a well-funded group with state-of-the-art molecular and cellular facilities. The lab fosters a supportive environment for staff and students, emphasizing career development and publication.

• Virology
• Ebola Virus Research
• Lassa Fever Virus
• +3 more

James Morgan Cunningham is an Associate Professor of Medicine (Microbiology and Molecular Genetics) at Brigham and Women's Hospital, affiliated with Harvard Medical School. His research focuses on viral entry mechanisms, particularly for Ebola and Lassa viruses, with a focus on developing antiviral therapies and understanding host-pathogen interactions. He has held part-time academic roles since at least 2024, as noted in his most recent publications. Research Interests: Dr. Cunningham's work spans viral pathogenesis, antiviral drug discovery, and the structural biology of viral glycoproteins. He has made significant contributions to understanding how cholesterol metabolism and cellular receptors (like LAMP1) influence viral entry. His research also explores the biochemical basis of Ebola glycoprotein activity during outbreaks and the development of small molecule inhibitors targeting enveloped viruses. Grants & Collaborations: He has secured NIH funding for projects like the New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases (2003-2015) and studies on small molecule inhibitors for viral entry (2014-2019). Notable collaborations include work with Sean Whelan on Ebola virus entry and Dennis Kasper on biodefense strategies. Publications: His work spans over three decades, with key contributions to understanding Ebola virus glycoprotein proteolysis (Science, 2005), Lassa fever virus cholesterol dependency (2018), and co-authorships with leaders in virology like Kartik Chandran and Kartik Chandran. Recent studies (2024) explore NAD metabolome changes in severe COVID-19 cases.

Marta GagliaView profile

Associate Professor

• Virology
• Molecular Virology
• Host-Pathogen Interactions
• +13 more

Marta Gaglia is an Associate Professor in the Department of Medical Microbiology and Immunology at the University of Wisconsin–Madison, School of Medicine and Public Health, and a member of the Institute for Molecular Virology and the Carbone Cancer Center. She leads an active research laboratory focused on virus-host interactions, particularly in influenza A virus and Kaposi’s sarcoma-associated herpesvirus (KSHV). Her lab relocated from Tufts University to UW–Madison in fall 2022, where she continues to mentor graduate students, postdoctoral researchers, and undergraduates. Her research centers on how viruses manipulate host innate immune responses, such as the cGAS/STING and interferon pathways, and how viral proteins like PA-X and ORF42 induce host shutoff and immune evasion. By studying both RNA and DNA viruses, her lab identifies conserved and unique mechanisms of viral subversion. The recent publications from her lab demonstrate a strong focus on molecular mechanisms of viral gene regulation, RNA degradation, and immune modulation. Her work combines biochemical, transcriptomic, and virological approaches to link molecular events to disease outcomes. Her scientific achievements have been recognized with awards such as the Ann Palmenberg Junior Faculty Award (2019) . Marta Gaglia mentors a diverse team of trainees and is a trainer in the Microbiology Doctoral Training Program (MDTP) and the Cell and Molecular Biology (CMB) program. Her lab has secured competitive grants, including an R01, supporting ongoing research. She fosters a collaborative and supportive lab culture, emphasizing mentorship and scientific excellence. The Gaglia Lab is actively involved in scientific outreach and community engagement, including participation in events during the pandemic and professional conferences. They also maintain a strong lab identity through team-building activities and celebrations of scientific milestones.

• Parasitology
• Biochemistry
• Molecular Biology
• +5 more

Nishith Gupta is a Professor specializing in parasitology and biochemistry with a research focus on apicomplexan parasites, particularly Toxoplasma gondii and Eimeria species. His work bridges molecular biology, lipid biochemistry, and host-pathogen interactions to understand the metabolic pathways essential for parasite survival and virulence. Humboldt-Universität zu Berlin: Habilitation in Biochemistry (2009-2017) Universität Leipzig: PhD in Biochemistry (1999-2003) Banaras Hindu University: MS in Biotechnology (1997-1999) Banaras Hindu University: Diploma in German Language (1997-1999) Rohilkhand University: BS in Biology (1994-1997) Professor Gupta's research centers on lipid metabolism in apicomplexan parasites, particularly focusing on phospholipid biosynthesis pathways in Toxoplasma gondii . His laboratory investigates how these parasites manipulate host cells, with special emphasis on calcium signaling, cyclic nucleotide pathways, and metabolic adaptations that support intracellular survival. His work has revealed novel drug targets related to phospholipid metabolism and ion homeostasis. Analysis of his recent publications shows a consistent focus on lipid-dependent processes in parasite biology, with particular attention to phosphatidylserine, phosphatidylethanolamine, and phosphatidylthreonine metabolism. His research demonstrates how these lipids regulate critical processes including host cell invasion, intracellular replication, and egress. The work spans molecular characterization of enzymes to physiological studies of parasite-host interactions. Multiple grants from Deutsche Forschungsgemeinschaft (DFG) on phospholipid metabolism in Toxoplasma Funding from Helmholtz Association for central carbon metabolism studies European Society of Clinical Microbiology and Infectious Diseases grant for drug target research Novartis Animal Healthcare contract for anti-Toxoplasma drug screening Professor Gupta's laboratory has made significant contributions to understanding how apicomplexan parasites manipulate host cells through lipid-mediated signaling. His team has developed innovative approaches including optogenetic tools to study cyclic nucleotide signaling in parasites. Current research focuses on metabolic plasticity, essential pathways for parasite survival, and identifying druggable targets in lipid metabolism.

Gary WardView profile

Professor

• Cell biology of host-parasite interaction
• Toxoplasma gondii
• Parasitology
• +3 more

Gary Ward, Ph.D. , is a Professor in the Department of Microbiology and Molecular Genetics at the Robert Larner, M.D. College of Medicine , University of Vermont. He directs the Vermont Immunobiology and Infectious Disease Training Program and leads the Ward Lab , focusing on the cell biology of host-parasite interactions in Toxoplasma gondii and related apicomplexan parasites. Dr. Ward's research encompasses: Mechanisms of parasite motility and host cell invasion Calcium signaling in apicomplexans Post-translational modifications (palmitoylation, phosphorylation) Apicomplexan cytoskeletal organization Small-molecule inhibitors of parasitic processes His lab has published extensively on Toxoplasma gondii motility (2013-2023), emphasizing: Myosin motor function Glideosome complex dynamics Three-dimensional invasion mechanics Chemical biology approaches to drug discovery Lab members include: Postdoctoral Fellows: Robyn Kent, Kaesi Morelli Graduate Students: Frances Male, Anne Snyder Senior Lab Technician: Anne Kelsen

Lanying ZengView profile

Professor

• Bacteriophage
• Quantitative biology
• Biophysics
• +4 more

Lanying Zeng is a Professor in the Department of Biochemistry and Biophysics at Texas A&M University, where she leads research at the intersection of virology, biophysics, and quantitative biology. Her work focuses on single-cell and single-molecule dynamics of bacteriophage infection cycles, employing high-resolution fluorescence microscopy and mathematical modeling to unravel fundamental mechanisms in viral decision-making processes. Education: Ph.D. in Theoretical and Applied Mechanics, University of Illinois at Urbana-Champaign (2007) Postdoctoral training in Quantitative Biology and Biophysics, University of Illinois at Urbana-Champaign (2007-2011) Research Focus: Dr. Zeng investigates cellular decision-making in phage systems, particularly the lysis-lysogeny switch in bacteriophages lambda and P1, and infection dynamics of ssRNA phages. Her lab pioneers quantitative approaches to understand how viruses make fate decisions through cooperation/competition mechanisms, RNA entry dynamics, and host structural impacts like F-pilus detachment. This research bridges fundamental virology with therapeutic applications for multi-drug resistant bacteria. Publication Trends: Her 2017-2024 publications reveal consistent innovation in single-cell viral dynamics, with increasing integration of super-resolution microscopy and computational modeling. Key themes include phage decision circuits operating at molecular scales, engineering principles of viral-host interactions, and translating basic mechanisms into phage therapy frameworks. Work published in Science, Nature Communications, and PNAS demonstrates leadership in quantitative virology. Research Group: Dr. Zeng directs an interdisciplinary laboratory that combines advanced imaging, genetic engineering, and theoretical modeling to dissect viral infection cycles, training researchers in quantitative biological approaches while advancing antibacterial therapeutic development.

Sankar SwaminathanView profile

Professor

• Virology
• Immunology
• Epigenetics
• +5 more

Dr. Sankar Swaminathan is a Professor of Internal Medicine and Adjunct Professor of Microbiology and Immunology at the University of Utah, where he also serves as the Chief of Infectious Diseases. His research program focuses on human cancer-causing herpesviruses, specifically Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), with NIH R01 funding sustained for over 25 years. He holds an A.B. from Harvard College and an M.D. from Emory University. Dr. Swaminathan's research explores three primary areas: Molecular interactions between herpesviruses (EBV/KSHV) and host cells, particularly how viral RNA-binding proteins target mRNAs to modulate gene expression. Role of interferon-stimulated genes (ISGs) in antiviral defense, studied both in vitro and in immunocompromised patients. Mechanisms by which host DNA-binding factors (CTCF/cohesin) restrict viral replication through topological interference. A fourth initiative involves antiviral drug discovery, leveraging high-throughput screening to identify compounds (e.g., spironolactone) that target herpesviral SM proteins. His publications emphasize virology, molecular mechanisms of herpesvirus replication, host-pathogen interactions, and therapeutic development. Recent work includes SARS-CoV-2/EBV co-infection studies and antiviral compound validation. No awards or student advisees are documented in the provided materials.

Mandy MullerView profile

Adjunct Associate Professor

• Virology
• Gamma-herpesvirus pathogenesis
• KSHV replication and latency
• +4 more

Adjunct Associate Professor Mandy Muller of the University of Massachusetts Amherst Department of Microbiology studies how gamma-herpesviruses—particularly Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)—re-shape host RNA metabolism to enable lifelong infection. Her NIH-funded group combines genome-wide sequencing, molecular virology and cell biology to uncover how viral nucleases target host mRNAs and how select antiviral transcripts escape decay. Education: PhD in Virology, Pasteur Institute (2013) Research Interests: Muller’s work centers on the interface of viral pathogenesis and RNA biology. She investigates (i) virus-induced mRNA degradation, (ii) host restriction factors that withstand this decay, (iii) epitranscriptomic modifications such as m6A that protect transcripts, and (iv) innate antiviral proteins like Shiftless that block viral gene expression and P-body dissolution. These studies illuminate fundamental cell-biology questions while identifying new targets for antiviral therapy. Publication Trends: Since 2019 her team has published >20 papers dissecting KSHV–host RNA interactions, revealing viral endonuclease substrates, RNA escape elements, and antiviral restriction mechanisms. The portfolio spans high-resolution molecular studies to genome-wide screens, consistently highlighting how herpesviruses hijack or evade host RNA regulatory networks. Grants & Awards: NIH MIRA R35 ($1.9 M, 2020-2025) Multiple trainee awards including Curt Thorne and David Pollack prizes Best talk & poster recognitions at regional meetings Advising & Mentorship: Nine PhD students have defended under her mentorship since 2021 (Yadi Bermudez, Jacob Miles, Tarah, Shai, David, Dr. MacVeigh-Fierro, Will Rodriguez, Jake, Tim), together with numerous MS and undergraduate researchers. Her laboratory emphasizes both research excellence and inclusive teaching, earning a CNS Excellence in Diversity and Inclusion group award. Laboratory & Outreach: The Muller Lab relocated to the Institute of Microbiology at the University of Lausanne (IMUL) in May 2025, continuing its work on viral RNA biology. Muller also engages in public communication through weekly radio segments (“The Muller Report”) separating virology fact from fiction for general audiences.

Dinh HuyView profile

Assistant Professor

• Computational Immunology
• Tumor Microenvironment
• Neutrophil Biology
• +12 more

Dinh Huy is an Assistant Professor in the Department of Oncology at the University of Wisconsin–Madison, School of Medicine and Public Health, and is based at the McArdle Laboratory for Cancer Research. His research focuses on the immune microenvironment in cancer and inflammation, with a particular emphasis on neutrophil biology and computational immunology. His research interests include: Understanding immune microenvironment heterogeneity and plasticity in cancer and wound healing Characterizing anti-tumoral neutrophil phenotypes induced by immunotherapy Identifying biomarkers in severe burn trauma using human and model organism samples Developing computational methods for multi-omics and single-cell data integration Comparing chronic inflammation in non-healing wounds and cancer His recent publications demonstrate a strong trend in leveraging single-cell and spatial transcriptomics to dissect myeloid cell dynamics in diverse disease contexts, including head and neck cancer, esophageal cancer, ovarian cancer, and burn injury. His work bridges computational biology with experimental validation, often in collaboration with clinical and basic science labs. Scientific awards and recognitions include: NIH funding awarded in 2023 Mentoring students who have received AACR Scholar-in-Training Awards (2024, 2025) Students receiving the Thomas and Bonnie Minter Graduate Student Cancer Research Award (2024), L&S Honors Summer Research Apprenticeship Award (2025), and Sophomore Research Fellowship (2025–2026) Dinh Huy actively mentors graduate students and postdocs, including Josh Brand and Athena Golfinos-Owens, both of whom have successfully defended their theses and transitioned to industry roles. His lab has secured competitive grants and fosters collaborative research, particularly in immunogenomics and precision medicine. He is also involved in training programs in Biomedical Data Science, Cancer Biology, and Microbiology. His lab, which includes postdocs like Hien Pham and graduate students such as Anqi, Zhili, and Sananda, focuses on computational and experimental approaches to understand neutrophil heterogeneity across inflammatory and oncogenic conditions.